Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘HRAS mutant’

Expect the unexpected

While there has been much speculation and rah-rah over the supposed demise of oral therapies thanks to the introduction of the Inflation Reduction Act (IRA) of 2022 including the Part D Redesign, I’m increasingly finding important developments on the targeted therapies front to watch out for.

In the third part of our ongoing mini-series on the PI3K and PIK3CA landscape we’re going to switch to a different example in this niche.

There are some key clinical data due out later this year, which ought to bear watching out for.

The question though, is why – and what ought we to be thinking about in a broader context?

Our latest article reviews the science, the players, the drugs, and explains how we got here…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

New path to market opportunity for Kura in SCCHN

Fall in Boston in time for TRIPLE19

Boston – It looks like being RAS week at the AACR-NCI-EORTC Triple meeting aka Targets19. Yesterday we explored the first-in-man data for the Mirati small molecule inhibitor, MRTX849, in KRASG12C mutant cancers that included lung and colon carcinomas.

In terms of aberrant activity in cancer, RAS comes in three different flavours, if you will – KRAS, NRAS, and HRAS.

After plenty of coverage of KRAS (and more yet to come!), it’s now time to turn our attention to a rather different oncogene driver and put HRAS to be in the spotlight.  Here, we offer an updated look at the progress of Kura Oncology’s tipifarnib in squamous cell carcinomas of the head and neck (SCCHN) and assess the potential opportunity for approval in this setting.

To learn more from our oncology coverage and get a heads up on insights from our latest thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!